Halberd (Halberd) EBIT : $ Mil (TTM As of Jul. 2023)

View and export this data going back to 2009. Start your Free Trial

What is Halberd EBIT?

Halberd's earnings before interest and taxes (EBIT) for the six months ended in Jul. 2023 was $-0.45 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Halberd's annualized ROC % for the quarter that ended in Jul. 2023 was -12,771.43%. Halberd's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jul. 2023 was -9,933.33%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield.

Halberd EBIT Historical Data

The historical data trend for Halberd's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Halberd EBIT Chart

Halberd Annual Data

Trend

Jul08

Jul22

Jul23

EBIT

-0.04

-1.62

-0.45

Halberd Semi-Annual Data
	Jul08	Jul22	Jul23
EBIT	-0.04	-1.62	-0.45

Competitive Comparison of Halberd's EBIT

For the Biotechnology subindustry, Halberd's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Halberd's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Halberd's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Halberd's EV-to-EBIT falls into.

Halberd EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. EBIT for the trailing twelve months (TTM) ended in Jul. 2023 was $ Mil.

Halberd (OTCPK:HALB) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Halberd's annualized ROC % for the quarter that ended in Jul. 2023 is calculated as:

	ROC % (Q: Jul. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jul. 2022 )	+	Invested Capital (Q: Jul. 2023 ))	/ count )
=	-0.447 * ( 1 - 0% )	/	( (0.004	+	0.003)	/ 2 )
=	-0.447	/	0.0035
=	-12,771.43 %

where

	Invested Capital		(Q: Jul. 2022 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.017	-	0.595	-	( 0.01	-	max(0, 0.595	-	0.013	+	0.01	))
=	0.004

	Invested Capital		(Q: Jul. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.012	-	0.789	-	( 0.007	-	max(0, 0.789	-	0.009	+	0.007	))
=	0.003

Note: The Operating Income data used here is one times the annual (Jul. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Halberd's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jul. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Jul. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jul. 2022		Q: Jul. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-0.447	/	( ( (0.005 + max(-0.592, 0))	+	(0.004 + max(-0.787, 0)) )	/	2 )
=	-0.447	/	( ( 0.005	+	0.004 )	/	2 )
=	-0.447	/	0.0045
=	-9,933.33 %

where Working Capital is:

	Working Capital		(Q: Jul. 2022 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.003)	-	(0.595	+	0	+	0)
=	-0.592

	Working Capital		(Q: Jul. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.002)	-	(0.789	+	0	+	0)
=	-0.787

When net working capital is negative, 0 is used.

Note: The EBIT data used here is one times the annual (Jul. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Halberd's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Jul. 2023 )
	=		/	5.231
	=	%

Halberd EBIT Related Terms

Thank you for viewing the detailed overview of Halberd's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Halberd (Halberd) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Halberd Corp (OTCPK:HALB) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

P.O. Box 25, Jackson Center, PA, USA, 16133

Website

https://www.halberdcorporation.com

Halberd Corp is a research-based biotechnology company seeking to discover and develop medical treatments for a range of diseases. The Company's extracorporeal treatment is designed to treat hard-to-cure blood-borne, neurologic and infectious diseases. The Company's patented methodology removes the appropriate bodily fluid from the patient, in a continuous fashion, like dialysis, or in a batch process, like blood sample testing.

Executives

John Christopher Maddox	director, 10 percent owner, officer: President, COO, Treasurer and, other: Interim CFO	10755 VERNON, HUNTINGTON WOODS MI 48070
Mark Sven Lundquist	director, 10 percent owner, officer: CEO, Secretary and Director	24655 TUDOR LANE, FRANKLIN MI 48025
Cocco Nicholas A. Jr.	director	50104 N. JIMMY COURT, CHESTERFIELD MI 48047-1898
Leland Michael Thomas	director	280 LASALLE PLACE, GROSSE POINTE FARMS MI 88236